DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

CHEMICO-BIOLOGICAL INTERACTIONS is a premier journal published by Elsevier Ireland Ltd, dedicated to advancing the field of chemical and biological interactions since its inception in 1969. With a robust focus on pharmacology and toxicology, the journal holds a prestigious Q1 ranking in both Medicine (miscellaneous) and Toxicology, reflecting its significance in disseminating influential research. As part of the Scopus database, it ranks #21 out of 133 journals in Toxicology, positioning it in the 84th percentile and ensuring high visibility for cutting-edge studies. This scholarly platform serves as a crucial resource for researchers, professionals, and students who seek reliable and innovative findings at the intersection of chemistry and biology. While currently not open access, CHEMICO-BIOLOGICAL INTERACTIONS provides a comprehensive collection of articles that contribute to the ongoing dialogue in toxin research and its implications on medicinal chemistry, thereby fostering advancements in public health and safety.

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

Marine Drugs is a leading peer-reviewed journal dedicated to the field of drug discovery and development derived from marine resources. Published by MDPI in Switzerland since 2003, this open-access journal has established itself as a prominent platform for the dissemination of high-quality research, evidenced by its Q1 rankings in 2023 across multiple categories including Drug Discovery, Pharmaceutical Science, and Pharmacology, Toxicology, and Pharmaceutics. With a global readership, Marine Drugs specializes in the exploration of bioactive compounds from marine organisms, advancing our understanding of natural product chemistry and its applications in pharmacology and therapeutics. The journal actively encourages submissions from researchers worldwide, showcasing innovative studies, reviews, and methodologies that contribute to the growing field of marine biotechnology. Researchers, professionals, and students alike will find Marine Drugs an invaluable resource for enhancing their knowledge and fostering collaborations in marine drug research.